Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry

• DOI: 10.1007/s11102-012-0460-2
• Publication Date: 2013-01-12T07:17:33Z
• Authors: Roberto Salvatori; Whitney W. Woodma...; Mark Molitch; Murray B. Gordon; Kathleen G. Lomax
• Keywords: Lanreotide; Demographics

Lanreotide depot (LD; commercial name Somatuline(®) Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide. In recent clinical trials, LD was found to be suitable for self or partner administration, avoiding need travel a medical facility. The Depot Acromegaly (SODA) study ongoing, multicenter, observational in US investigating efficacy, safety, convenience and symptom relief provided by patients with acromegaly. Sub-analyses explore outcomes according who administered injection: patient, partner, healthcare provider (HCP) combination. Data reported here reflect one year patient experience. Patients are eligible inclusion if they have diagnosis acromegaly, treated can give signed informed consent. Baseline data include demographics, previous acromegaly treatment investigations, GH IGF-I levels, dose adjustment frequency. Symptom frequency, injection pain assessed using patient-reported questionnaires. As 18 April 2012, 166 had enrolled SODA. Most (72 %) achieved normal levels after 12 months treatment. Disease control similar injectors received injections from their HCP, although injecting deemed more convenient. well-tolerated irrespective performed injection. Self led injection-site reactions, but this did not increase rate interruption. symptoms remained stable. Biochemical, safety support validity at home.